Q1 EPS Forecast for Rapport Therapeutics Boosted by Analyst

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – Research analysts at HC Wainwright lifted their Q1 2026 earnings estimates for Rapport Therapeutics in a report released on Wednesday, March 11th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.65) for the quarter, up from their previous estimate of ($0.76). HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($2.40) EPS, FY2027 earnings at ($3.56) EPS, FY2028 earnings at ($4.65) EPS and FY2029 earnings at ($4.78) EPS.

Other research analysts have also issued reports about the company. TD Cowen reaffirmed a “buy” rating on shares of Rapport Therapeutics in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. The Goldman Sachs Group restated a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Wells Fargo & Company raised their price objective on Rapport Therapeutics from $43.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, BTIG Research lifted their price objective on Rapport Therapeutics to $47.00 and gave the company a “buy” rating in a research note on Monday. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Rapport Therapeutics Stock Down 2.9%

Shares of RAPP opened at $27.84 on Friday. Rapport Therapeutics has a fifty-two week low of $7.73 and a fifty-two week high of $42.27. The company’s fifty day moving average is $28.10 and its two-hundred day moving average is $26.99. The firm has a market cap of $1.33 billion, a PE ratio of -9.73 and a beta of 1.51.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.07).

Hedge Funds Weigh In On Rapport Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RAPP. Baker BROS. Advisors LP boosted its holdings in Rapport Therapeutics by 181.2% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock worth $45,949,000 after acquiring an additional 997,000 shares during the period. Vestal Point Capital LP purchased a new stake in shares of Rapport Therapeutics during the third quarter valued at approximately $28,215,000. Polar Capital Holdings Plc acquired a new position in shares of Rapport Therapeutics during the third quarter worth $27,887,000. Capital International Investors lifted its position in shares of Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after purchasing an additional 800,000 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Rapport Therapeutics by 265.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company’s stock valued at $26,500,000 after purchasing an additional 648,378 shares during the period.

Insider Buying and Selling

In related news, COO Cheryl Gault sold 2,014 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $28.93, for a total value of $58,265.02. Following the completion of the sale, the chief operating officer directly owned 169,914 shares in the company, valued at approximately $4,915,612.02. This represents a 1.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Abraham Ceesay sold 5,083 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $29.36, for a total value of $149,236.88. Following the completion of the transaction, the chief executive officer directly owned 20,729 shares in the company, valued at $608,603.44. This trade represents a 19.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 69,669 shares of company stock valued at $1,999,877 in the last 90 days. 13.57% of the stock is currently owned by company insiders.

Key Stories Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple near‑term EPS forecasts for RAPP (Q1–Q4 2026 and FY2026) and lifted FY2027/FY2028 estimates, while maintaining a “Buy” rating and a $40 price target — supportive for upside if clinical or commercial progress continues. Read More.
• Neutral Sentiment: HC Wainwright posted a FY2030 EPS projection (longer‑range modeling) that is not an immediate driver of near‑term price action but signals analyst coverage continues to model multi‑year outcomes. Read More.
• Neutral Sentiment: A Globenewswire filing posted preparatory materials for a March 27 corporate meeting (annual report/AGM materials). This appears administrative and unlikely to be material to near‑term stock moves. Read More.
• Negative Sentiment: RAPP reported an earnings miss (reported March 10), which triggered a gap‑down and sell‑off; one article highlights the immediate downward reaction and higher trading volume as investors reprice near‑term performance risk. Read More.
• Negative Sentiment: Although many near‑term estimates were raised, HC Wainwright materially worsened its FY2029 EPS forecast (larger loss), which increases uncertainty about later‑stage profitability and may weigh on longer‑dated investor expectations. Read More.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.